Company / Total Assets
4D Molecular Therapeutics, Inc. Total Assets History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$566.7M
FY2025
5-year range
$261.8M / $566.7M
FY2021-FY2025
Trend
+1.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has increased for 3 consecutive years, from $262M in FY2022 to $567M in FY2025.
Based on SEC 10-K filings.
$567M in FY2025 with a 5-year CAGR of +14.5%.
Improved from $340M to $567M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- +29.4%
- 5-Year CAGR
- +14.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 4D Molecular Therapeutics, Inc.'s total assets has grown for 3 consecutive years.
- 5-year CAGR of +14.5%, indicating consistent growth.
- In FY2025, total assets increased 1.1% year-over-year.
- Lowest total assets in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $566.7M | +1.1% |
| FY2024 | $560.4M | +64.9% |
| FY2023 | $339.9M | +29.8% |
| FY2022 | $261.8M | -25.9% |
| FY2021 | $353.5M | +22.6% |
| FY2020 | $288.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026